CVE:EPI ESSA Pharma (EPI) Stock Price, News & Analysis → We recommended Nvidia in 2016, now we’re recommending this… (From Porter & Company) (Ad) Free EPI Stock Alerts C$8.20 +0.55 (+7.19%) (As of 10/30/2020) Add Compare Share Share Today's RangeC$7.33▼C$8.2050-Day RangeC$8.20▼C$8.2052-Week RangeC$4.00▼C$11.34Volume1,430 shsAverage Volume4,834 shsMarket CapitalizationC$237.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ESSA Pharma alerts: Email Address Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About ESSA PharmaESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.Read More EPI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPI Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive EPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:EPI CUSIPN/A CIKN/A Webessapharmaceuticals.com Phone+1-778-3310962FaxN/AEmployees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio37.29 Quick Ratio36.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$2.21 per share Price / Cash Flow3.72 Book ValueC$2.21 per share Price / Book3.72Miscellaneous Outstanding Shares29,009,000Free FloatN/AMarket CapC$237.87 million OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. David Ross Parkinson (Age 71)Pres, CEO & Director Comp: $626.81kMr. David S. Wood C.M.A. (Age 64)CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer Comp: $311.52kMr. Peter A. Virsik M.B.A. (Age 50)M.S., Exec. VP & COO Comp: $544.66kDr. Alessandra CesanoChief Medical OfficerChandtip ChandhasinExec.Erica OsbourneExec.Erin RudsinskiExec.Leah DimascioExec.Loleta HarrisExec.Neil ThaparExec.More ExecutivesKey CompetitorsHydropothecaryCVE:THCXCanopy GrowthTSE:WEEDKnight TherapeuticsTSE:GUDAurora CannabisTSE:ACBSupreme CannabisTSE:FIREView All Competitors EPI Stock Analysis - Frequently Asked Questions How have EPI shares performed in 2024? ESSA Pharma's stock was trading at C$8.20 on January 1st, 2024. Since then, EPI stock has increased by 0.0% and is now trading at C$8.20. View the best growth stocks for 2024 here. Is ESSA Pharma a good dividend stock? ESSA Pharma (CVE:EPI) pays an annual dividend of C$0.22 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include Aurora Cannabis (ACB), Air Canada (AC), Arbutus Biopharma (ABUS), AB Science (ABSCF), AB International Group (ABQQ), AB Dynamics (ABDP), Advantage Energy (AAV), AA (AATDF), AAON (AAON) and AAC Technologies (AACAY). How do I buy shares of ESSA Pharma? Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:EPI) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.